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How should cancer presenting as a malignant pleural effusion be managed?
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Summary The objective of the study was to review the natural history of patients with a malignant pleural
effusion but without obvious evidence of a primary, to assess the value of investigations used to look for a
primary and to assess the response to palliative chemotherapy. This was done by a retrospective study of
patients' notes at the Lung Unit, Royal Marsden Hospital, Sutton, Surrey. Improvement in tumour-related
symptoms (and duration) on chemotherapy was assessed by the patient before the first course ofchemotherapy
and following each course using simple descriptive criteria as follows: (1) complete disappearance of symptoms
(CR); (2) good improvement in symptoms (PR); (3) minor or no change in symptoms (NC); (4) worse
symptoms (PD). Pleural effusion objective response (and duration) according to Hamed definition: success
defined as a continued absence of reaccumulation of pleural fluid on all follow-up radiographs; any
reaccumulation was regarded as a treatment failure. Overall survival was measured from the date of
histological/cytological diagnosis to death. The study included 42 patients, 27 males and 15 females with a
median age of 55 years. A primary was found in 15 patients (36%), and considered to be lung cancer. A total
of 11/32 (34%) had a thoracic computed tomography (CT) scan with abnormalities compatible with a
diagnosis of lung primary. When thoracic CT scan was negative, fibre optic bronchoscopy was always negative
(0/13). Abdominal and pelvic CT scan, abdominal ultrasound, pelvic ultrasound and mammograms failed to
reveal the primary. Twenty-three patients underwent local treatment and 37 received systemic chemotherapy. A
total of 29/37 (78%) patients achieved symptomatic improvement (median duration, 6 months) and 32/37
(86%) an objective response of their pleural effusion on chemotherapy (median duration, 6 months). The
median survival of the whole group was 12 months (3-60+ months). In this series the thoracic CT led to a
diagnosis of lung primary in 34% of the cases. Other radiological examinations and bronchoscopy were
unhelpful. Chemotherapy achieved symptom relief in 78% of patients.
Keywords: malignant pleural effusion; unknown primary carcinoma
Malignant pleural effusion from an unknown primary is a
common presenting problem in cancer medicine and is
reported as accounting for 12% of all presentations of
unknown primary carcinoma (Abbruzzese et al., 1994).
Moreover, between 6 and 15% of all malignant pleural
effusions are from an unknown primary (Ringenberg and
Yarbro, 1986; Sears and Hajdu, 1987).
Several studies have assessed the value of an extensive
series of 'hunt the primary' investigations in patients with
carcinoma of unknown primary affecting different sites
(Nystrom et al., 1979; Stewart et al., 1979; Steckel and
Kagan, 1980), but for patients presenting with a malignant
pleural effusion of uncertain primary, there is no clearly
defined management policy (Ringenberg and Yarbro, 1986).
Likewise there is no clearly defined policy for treatment.
Most published data are about local treatment: these include
instillation ofintrapleural sclerosing agents such as bleomycin
(Hamed et al., 1989; Ruckdeschel et al., 1991), tetracycline
(Fentiman et al., 1986; Ruckdeschel et al., 1991), talc (Hamed
et al., 1989; Fentiman et al., 1986), iodised talc (Webb et al.,
1992) and, more recently, pleuroperitoneal shunts (Little et
al., 1988; Tsang et al., 1990). For systemic chemotherapy for
carcinomas of unknown primary, the survival impact has
been assessed in a few studies (Woods et al., 1980;
Hainsworth et al., 1992; Abbruzzese et al., 1994), but not
specifically for pleural effusions; moreover we are unaware of
any published attempt to assess the symptomatic benefit of
this approach.
We have therefore retrospectively reviewed 42 consecutive
patients referred to the Royal Marsden Hospital with a
malignant pleural effusion as the presenting clinical problem
but without obvious evidence of a primary. We have assessed
the value of the investigations used to look for a primary and
reviewed the natural history and response to palliative
chemotherapy.
Patients and methods
The clinical records of 42 consecutive patients referred to the
Lung Unit at the Royal Marsden Hospital from 1985 to 1994
with a malignant pleural effusion as the presenting clinical
problem but without evidence of a primary were retro-
spectively reviewed. Patients with pleural effusion as an
incidental finding to other overt clinical or radiological
features of cancer were excluded (e.g. in association with
previously established breast or lung cancer).
Of these patients 27 were males and 15 females with a
median age of 55 years (range 33-74 years). WHO
performance status was as follows: PS 0, five patients; PS
1, 26 patients; PS 2, ten patients; PS 3, one patient.
All patients had detailed history and clinical examination
with particular emphasis on examination of breasts, prostate
and testes. All patients also had a standard full blood count,
serum liver function tests and chest radiograph. In addition,
the following further investigations were carried out: CT scan
of thorax (32 patients), fibre optic bronchoscopy (23
patients), abdominal CT scan or ultrasound (37 patients),
mammography (ten patients) and pelvic ultrasound (ten
female patients).
Twenty-three patients received local treatment including
pleural aspiration to dryness with intrapleural bleomycin
(seven patients), tetracycline (ten patients), talc (four
patients), pleuroperitoneal shunts (two patients, after
intrapleural tetracycline in one) and surgical pleural
decortification (one patient). Thirty-seven patients received
chemotherapy. In 17 of these, this was after local treatment
in patients with persisting or progressive symptoms. In two
patients this was concurrent with local treatment but for
symptoms (pain and cough) considered independent of the
effusion. In two patients this was before local treatment
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March 1996which was given subsequently (1) because of failure of
chemotherapy; (2) 7 months later following response and
then relapse. In all 17 therefore it was possible to make an
independent assessment of chemotherapy outcome. Che-
motherapy schedules were as follows: MVP (25 patients),
MCF (five patients), ECF (two patients), (details of these
chemotherapy regimens are in Table I), or phase II
experimental treatment with mitozolamide (one patient),
zeniplatin (two patients), carboplatin (one patient) and
infusional etoposide (one patient).
Tumour-related symptoms were recorded at the start of
treatment independently of the medical team by research
nurses under the following headings: malaise, pain, cough,
dyspnoea or 'other' which was then specified. Symptoms were
then reassessed following each course of treatment with
patients asked to grade change in symptoms using simple
descriptive criteria as follows: (1) complete disappearance of
symptoms (CR); (2) good improvement of symptoms (PR);
(3) minor or no change of symptoms (NC); and (4) worse
(PD).
Formally, a pleural effusion is not considered a
measurable lesion for response by standard WHO criteria
(Miller et al., 1981). For the purposes of this study, we used
the method of assessing response previously described by
Hamed et al. (1989). A chest radiograph was taken before the
first chemotherapy and used as a baseline from which to
assess subsequent chest radiographs. Success was defined as a
continued absence of reaccumulation of pleural fluid on all
follow-up radiographs; any reaccumulation was regarded as a
treatment failure.
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median duration of objective response was also 6 months
(range 4 weeks-16 months). The overall survival for the
whole group from the date of histological/cytological
diagnosis was 12 months with a range of 3-60+
months (see Figure 1). There was no significant survival
difference between men and women. The median survival
of patients in whom the primary was found (lung cancer)
was only 7.5 months, compared with 16 months for those
in whom no primary could be found (P<0.005) (see
Figure 2).
Table I Chemotherapy regimens
MVP Mitomycin C
Vinblastine
Cisplatin
MCF Mitomycin C
Cisplatin
5-Fluorouracil
ECF Epirubicin
Cisplatin
5-Fluorouracil
8 mgm-2 i.v. day 1 (given on alternate
course)
6 mgm2 i.v. day 1 every 3 weeks
50 mgm-2 i.v. in 250ml 0.9% saline over
1 h over every 3 weeks
8 mgm-2 i.v. day 1 (given on alternate
courses)
75 mgm2 i.v. in 250ml 0.9% saline over
1 h every 4 weeks
200 mgm-2 every 24h continuous i.v.
fusion for 6 months
50 mgm-2 i.v. bolus every 3 weeks for six
courses
60 mgm-2 i.v. in 250ml 0.9% saline over
1 h every 3 weeks
200 mgm-2 every 24h continuous i.v.
infusion for 6 months
Results
Pleural effusions were diagnosed histologically or cytologi-
cally as being of the following subtypes: adenocarcinoma (33
patients), undifferentiated large-cell carcinoma (five patients),
poorly differentiated squamous cell carcinoma (three
patients), small-cell carcinoma (one patient). Following
appropriate investigations the primary was found in only 15
patients (36%): 5/15 females (33%) and 10/27 males (37%).
In all these patients this proved to be lung cancer. Of 32 CT
thoracic scans 11 showed abnormalities compatible with a
diagnosis of lung primary (lung opacity, atelectasis and/or a
mediastinal mass).
Fibre optic bronchoscopy demonstrated lung cancer in
only 3/23 examinations (13%). In the other 20 patients no
abnormalities indicative of cancer were found, either
macroscopically or on biopsy. In 13 patients who had both
a negative CT scan of the thorax and underwent fibre optic
bronchoscopy, the fibre optic bronchoscopy was always
negative. None of the 37 abdominal CT scans or ultrasound
scans revealed the primary. This examination showed
evidence of metastatic disease in only a minority of
patients: this included ascites (four patients), adrenal
involvement (one patient), hemi-diaphragmatic tumour
nodules (one patient) and a renal metastasis (one patient).
In the ten female patients who had mammograms, none
showed evidence of breast cancer. Likewise pelvic ultra-
sound in seven female patients all failed to demonstrate a
primary.
In 37 patients who received chemotherapy, 29 (78%)
achieved useful symptomatic response, including eight (22%)
who achieved complete resolution of symptoms; assessed
independently of local treatment as outlined in Patients and
methods. This included 28/32 on standard chemotherapy (i.e.
MVP, MCF or ECF) and 4/5 on experimental treatments
(mitozolomide, zeniplatin).
Thirty-two out of 37 patients (86%) achieved an objective
response as previously defined. This included 28/32 on
standard chemotherapy as defined above and 4/5 on
experimental chemotherapy.
The median duration of chemotherapy-induced symp-
tom response was 6 months (range 2- 18 months). The
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Figure 1 Overall survival since diagnosis. All patients, n=42.
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Figure 2 Overall survival since diagnosis. ( ), primary
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Discussion
This series of patients suggests that the prognosis is poor in
patients presenting with a malignant pleural effusion from an
unknown primary. with a median survival of 12 months and
10% still alive at 2 years. A similar observation was made by
Abbruzzese et al. (1994) in a large subgroup of patients with
malignant pleural effusion from unknown primary carcino-
mas. Patients presenting with a malignant pleural effusion did
particularly badly with a median survival of around 6 months
and no one alive for more than 20 months. In contrast.
patients presenting with ly-mph node metastatic disease had a
median survival of 40 months.
This study confirms previous reports (Nystrom et al.. 1979;
Stewart et al.. 1979; Steckel et al.. 1980) that elaborate
investigations to 'hunt the primary' are likely to be negative
in the majority of patients. The most effective investigation
was a CT scan of the thorax which detected a lung primary in
11 32 patients (34%). In contrast. a bronchoscopy proved
positive in only 3 23 (13%) of patients and was never positive
after a negative CT scan. A bronchoscopy. although
frequently carried out for this clinical problem, is therefore
unhelpful in patients with a negative CT scan and appears to
contribute little further in patients with a positive CT scan
showing abnormalities compatible with the diagnosis of a
lung primarv. We therefore question its value in the
investigation of this condition. These observations are
confirmed in another analysis. in which 17 patients with a
malignant pleural effusion but without a mass or atelectasis
on chest radiograph underwent a bronchoscopy (Feinsilver et
al.. 1986). This examination demonstrated bronchogenic
carcinoma in two patients (12%). The authors concluded
that bronchoscopy for this indication should not be routinely
employed. In our series. other investigations. including
abdominal CT or ultrasound. mammography and pelvic
ultrasound were uniformly unhelpful. There may. however.
have been a biased selection here since our patients were
specifically referred to the Lung Unit.
It is commonly agreed that a search for a primary is
important to detect potentially treatable conditions such as
ovarian or breast cancer. In one study of 66 patients
presenting with pleural effusion of uncertain primary. an
ovarian primary was found in 9 42 patients (21%), three
patients presenting concurrently with ascites (Sears and
Hajdu. 1987). In our own recent review of 192 patients
with stage IV ovarian carcinoma referred to the Royal
Marsden Hospital. 63 patients presented with a pleural
effusion (personal observation). The median overall survival
of these patients however was only 13 months irrespective of
their subsequent treatment. This indicates that the median
survival of patients with a pleural effusion from an ovarian
primary is similar to those with an unknown primary and
suggests little clinical gain in establishing this diagnosis. For
breast cancer. pleural effusions are common. but usually as a
delayed event, months or years after the diagnosis of the
breast primary. The mean time between the diagnosis of
breast cancer and the development of a subsequent pleural
effusion was 41.5 months in one study (range 0-246 months)
with only 8.5% of the patients presenting with a pleural
effusion within 9 months of the diagnosis of the primary
(Fentiman et al.. 1981) and 52 months in another (range 1-
240 months) with no patient presenting as a pleural effusion
of unknown primary (Sears et al.. 1987). A breast primary
presenting as a pleural effusion is therefore uncommon. The
detection in effusions of hormone receptors by immunocy-
tochemistry (Kiang and Kennedy. 1977; Masood, 1992) or
the use of selected combinations of monoclonal antibodies to
tumour-associated antigens (Mottolese et al.. 1988) could
help. Finally. if this diagnosis appeared possible, the
pragmatic prescription of tamoxifen could be considered.
A feature of our study was that chemotherapy achieved
symptom relief and an objective response (as previously
defined) in a large majority of patients so treated (in 78%
and 86% of cases respectively). The MVP schedule has been
shown to achieve similar symptomatic clinical benefit with a
32% objective response rate (WHO definition) in patients
with non-small-cell lung cancer (Ellis et al.. 1995). Likewise.
Hainsworth et al. (1992) reported that platinum-based
chemotherapy for patients presenting with poorly differen-
tiated or undifferentiated unknown primary carcinoma was
associated with a high objective response rate (63%).
However, the response rate should not be the only goal in
a disease with such a bad prognosis and palliation must be
considered.
In conclusion. patients presenting with a malignant pleural
effusion and no obvious primary site have a poor prognosis.
An extensive search for a primary is usually unrewarding
and, in particular, fibre optic bronchoscopy is rarely positive.
Palliative chemotherapy may achieve useful but short-term
symptom relief in a majority of patients.
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